Site icon Market Stats News

CAR T-Cell Therapy Market Size To Cross USD 6.43 Bn By 2032

The global CAR T-cell therapy market size accounted for US$ 2.19  Bn in 2022 and is projected to reach around USD 6.43  Bn by 2032, growing at a CAGR of 11.37% from 2023 to 2032.

CAR T Cell Therapy Market Size 2023 To 2032 Precedence Statistics

Report Summary

The global CAR T-cell therapy market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the CAR T-cell therapy market across the globe.

A comprehensive estimate on the CAR T-cell therapy market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of CAR T-cell therapy during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2545

CAR T-Cell Therapy Market Report Scope 

Report Coverage Details
Market Size in 2023 USD 2.44 Billion
Market Size by 2032 USD 6.43 Billion
Growth Rate from 2023 to 2032 CAGR of 11.37%
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Drug Type, By Indication and By End User

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized CAR T-cell therapy market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: Newborn Eye Imaging Systems Market Size Analysis 2023 To 2032

CAR T-Cell Therapy Market Players

The report includes the profiles of key CAR T-cell therapy market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

Market Segmentation

By Drug Type

By Indication

By End User

Regional Segmentation

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on CAR T-Cell Therapy Market 

5.1. COVID-19 Landscape: CAR T-Cell Therapy Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global CAR T-Cell Therapy Market, By Drug Type

8.1. CAR T-Cell Therapy Market, by Drug Type, 2022-2032

8.1.1 Axicabtagene Ciloleucel

8.1.1.1. Market Revenue and Forecast (2022-2032)

8.1.2. Tisagenlecleucel

8.1.2.1. Market Revenue and Forecast (2022-2032)

8.1.3. Brexucabtagene Autoleucel

8.1.3.1. Market Revenue and Forecast (2022-2032)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2022-2032)

Chapter 9. Global CAR T-Cell Therapy Market, By Indication

9.1. CAR T-Cell Therapy Market, by Indication, 2022-2032

9.1.1. Lymphoma

9.1.1.1. Market Revenue and Forecast (2022-2032)

9.1.2. Acute Lymphocytic Leukemia

9.1.2.1. Market Revenue and Forecast (2022-2032)

9.1.3. Chronic Lymphocytic Leukemia (CLL)

9.1.3.1. Market Revenue and Forecast (2022-2032)

9.1.4. Multiple Myeloma (MM)

9.1.4.1. Market Revenue and Forecast (2022-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2022-2032)

Chapter 10. Global CAR T-Cell Therapy Market, By End User 

10.1. CAR T-Cell Therapy Market, by End User, 2022-2032

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2022-2032)

10.1.2. Cancer Treatment Centers

10.1.2.1. Market Revenue and Forecast (2022-2032)

Chapter 11. Global CAR T-Cell Therapy Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.1.2. Market Revenue and Forecast, by Indication (2022-2032)

11.1.3. Market Revenue and Forecast, by End User (2022-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.1.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.1.4.3. Market Revenue and Forecast, by End User (2022-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.1.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.1.5.3. Market Revenue and Forecast, by End User (2022-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.2.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.3. Market Revenue and Forecast, by End User (2022-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.2.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.4.3. Market Revenue and Forecast, by End User (2022-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.2.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.5.3. Market Revenue and Forecast, by End User (2022-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.2.6.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.6.3. Market Revenue and Forecast, by End User (2022-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.2.7.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.7.3. Market Revenue and Forecast, by End User (2022-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.3.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.3. Market Revenue and Forecast, by End User (2022-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.3.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.4.3. Market Revenue and Forecast, by End User (2022-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.3.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.5.3. Market Revenue and Forecast, by End User (2022-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.3.6.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.6.3. Market Revenue and Forecast, by End User (2022-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.3.7.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.7.3. Market Revenue and Forecast, by End User (2022-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.3. Market Revenue and Forecast, by End User (2022-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.4.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.4.3. Market Revenue and Forecast, by End User (2022-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.4.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.5.3. Market Revenue and Forecast, by End User (2022-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.4.6.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.6.3. Market Revenue and Forecast, by End User (2022-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.4.7.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.7.3. Market Revenue and Forecast, by End User (2022-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.5.3. Market Revenue and Forecast, by End User (2022-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.5.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.5.4.3. Market Revenue and Forecast, by End User (2022-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.5.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.5.5.3. Market Revenue and Forecast, by End User (2022-2032)

Chapter 12. Company Profiles

12.1. Kolon TissueGene, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. JCR Pharmaceuticals Co., Ltd.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Kolon TissueGene, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. JCR Pharmaceuticals Co., Ltd.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. MEDIPOST

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. PHARMICELL Co., Ltd.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. ANTEROGEN. CO., LTD

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Bristol-Myers Squibb Company

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Novartis AG

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Gilead Sciences, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com

Exit mobile version